President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.
Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.
PTC Therapeutics announced interim data from part 1 of the company’s open-label clinical trials of risdiplam (RG7916) for Type 1, 2 and 3 spinal muscular atrophy (SMA).
Sanofi SA’s skin cancer drug Libtayo, made in partnership with Regeneron Pharmaceuticals Inc., was approved by the U.S. Food and Drug Administration.
Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.
The U.S. Food and Drug Administration approved Eli Lilly and Co.’s migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.
Merck & Co. Inc. Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019 after scrapping a policy requiring the drugmaker’s CEOs to retire at the age of 65.
Gilead Sciences Inc. plans to launch generic versions of the company’s hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.
Prescription drug shortages may drive up prices twice as much as they would rise with medicines in abundant supply, adding $230 million a year to U.S. drug costs, a new study estimates.
Health authorities in England rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing Kymriah’s use in children and young people.
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.
Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.
Shares of Israeli drugmaker Teva Pharmaceutical Industries rose more than 5 percent after the U.S. Food and Drug Administration approved the company’s new migraine treatment.
Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).
Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve the company’s drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).
U.S. health regulators approved Tetraphase Pharmaceuticals Inc.’s drug to treat complicated intra-abdominal infections.
Novartis received European approval for Kymriah, the Swiss drugmaker’s gene-modifying therapy for blood cancer.
U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.
Express Scripts Holding Co. built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now the pharmacy benefit manager is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.